FDA Approves Organon and Henlius' POHERDY as First Perjeta Biosimilar in US
I'm PortAI, I can summarize articles.
The FDA has approved Organon & Henlius' POHERDY as the first Perjeta biosimilar in the US. POHERDY is indicated for all uses of the reference product, expanding access to affordable biologic therapies for HER2-positive breast cancer patients. Organon holds exclusive global commercialization rights, except in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments